Science Explorer Interactive view Map
Topic · Molecular Biology

Inflammasome and immune disorders

Inflammasome and immune disorders is a research topic within Molecular Biology. Science Explorer counts 26k research works in it since 1950. 25.8% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the molecular mechanisms of inflammasome activation, regulation, and its role in inflammatory responses, cell death (pyroptosis), and immune-related diseases. It covers topics such as NLRP3 inflammasome, interleukin-1, caspase-1, and the involvement of mitochondria in inflammasome activation.

  • Inflammasome
  • NLRP3
  • Pyroptosis
  • Interleukin-1
  • Caspase-1
  • Inflammation
  • Cell Death
  • Immune Response
  • Mitochondria
  • Autoinflammatory Diseases
Research works
26k
fractional, since 1950
In the world top 10%
6.8k
per year above
Top-10% rate
25.8%
share of its works in the world top 10%
Growth, 2013–17 → 2018–22
+84%
the tick is no change

Which countries lead Inflammasome and immune disorders research?

By volume, China and the United States publish the most (4.1k and 1k works in 2022–2025).

By volume, 2022–2025

  1. 1 China 4.1k works
  2. 2 United States 1k works
  3. 3 Türkiye 282 works
  4. 4 Germany 252 works
  5. 5 India 235 works
  6. 6 Italy 212 works
  7. 7 Japan 205 works
  8. 8 South Korea 164 works
  9. 9 United Kingdom 163 works
  10. 10 France 158 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 60.1%United States: 15.2%Türkiye: 4.2%Germany: 3.7%6 others listed: 16.8%60%largest
China4,068 · 60.1%United States1,029 · 15.2%Türkiye282 · 4.2%Germany252 · 3.7%6 others listed1,137 · 16.8%

Shares of the rows listed above, not of the whole node.

Which institutions lead Inflammasome and immune disorders research?

By volume in 2022–2025, Chinese Academy of Medical Sciences & Peking Union Medical College publishes the most Inflammasome and immune disorders research, followed by Central South University and Sun Yat-sen University.

By volume, 2022–2025

  1. 1 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 59 works
  2. 2 Central South UniversityChina 48 works
  3. 3 Sun Yat-sen UniversityChina 46 works
  4. 4 Nanjing Medical UniversityChina 44 works
  5. 5 Sichuan UniversityChina 37 works
  6. 6 Wuhan UniversityChina 36 works
  7. 7 Anhui Medical UniversityChina 35 works
  8. 8 Shanghai Jiao Tong UniversityChina 35 works
  9. 9 Huazhong University of Science and TechnologyChina 35 works
  10. 10 Nanjing University of Chinese MedicineChina 35 works

Where is Inflammasome and immune disorders research done?

The largest centres of Inflammasome and immune disorders research in 2022–2025 are Beijing (China), Guangzhou (China), Shanghai (China) and Nanjing (China). Among places with at least 20 works in it, it is an unusually large share of all research in Luzhou, Zunyi and Hengyang.

Largest cities, 2022–2025

  1. 1 Beijing China 385 works
  2. 2 Guangzhou China 298 works
  3. 3 Shanghai China 288 works
  4. 4 Nanjing China 199 works
  5. 5 Wuhan China 169 works
  6. 6 Changsha China 151 works
  7. 7 Hangzhou China 150 works
  8. 8 Chengdu China 131 works
  9. 9 Hefei China 108 works
  10. 10 Jinan China 107 works

Where it is the local speciality

  1. LuzhouCN · 25.4 works13×
  2. ZunyiCN · 20.8 works12×
  3. HengyangCN · 30.4 works11×
  4. WenzhouCN · 62.0 works8.7×
  5. XuzhouCN · 22.2 works7.9×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Inflammasome and immune disorders than the world average.

See Inflammasome and immune disorders on the map

Where is the best place to study Inflammasome and immune disorders?

Among universities, judged by research, Southern Medical University, China Medical University and China Pharmaceutical University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 36.49%fractional works in this node (log) →share in the world top 10% →Southern Medical University: 35, 36.9%China Medical University: 32, 45.2%China Pharmaceutical University: 24, 44.1%Guangzhou Medical University: 27, 36.2%Wenzhou Medical University: 33, 32.1%Chinese Academy of Medical Sciences & Peking Union Medical College: 59, 31.3%Shanghai University of Traditional Chinese Medicine: 25, 36.5%Chongqing Medical University: 31, 31.8%Anhui Medical University: 35, 34.7%Dalian Medical University: 21, 36.1%China Medical Univer…China Pharmaceutical…Southern Medical Uni…Guangzhou Medical Un…
above the meannear itbelow it

One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.

#UniversityScoreTop 10%SpecialisationWorksGrowth
1 Southern Medical UniversityChina 74.736.9%11.9×35 +231.5%
2 China Medical UniversityChina 74.345.2%12.2×32 +150.4%
3 China Pharmaceutical UniversityChina 74.244.1%14.0×24 +370.1%
4 Guangzhou Medical UniversityChina 72.436.2%12.4×27 +224.6%
5 Wenzhou Medical UniversityChina 71.132.1%11.8×33 +323.1%
6 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 70.831.3%7.5×59 +203.8%
7 Shanghai University of Traditional Chinese MedicineChina 70.236.5%16.1×25 +314.2%
8 Chongqing Medical UniversityChina 69.931.8%11.5×31 +602.6%
9 Anhui Medical UniversityChina 68.634.7%14.6×35 +133.1%
10 Dalian Medical UniversityChina 68.136.1%13.4×21 +455.5%

Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.

Is Inflammasome and immune disorders research growing?

Output in 2018–2022 was 84% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Inflammasome and immune disorders.

19801990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.